Abstracts Archive - Page 2007 of 2607 - ACR Meeting Abstracts

Abstract Number: 2044 • 2015 ACR/ARHP Annual Meeting
Axonal Dysfunction in Childhood-Onset Systemic Lupus Erythematosus. Association with Neuropsychiatric Manifestations and Disease Activity
Renan Frittoli¹, Mariana Postal², Karina Pelicari², Nailu Sinicato³, Aline Tamires Lapa⁴, Fernando Peres¹, Fernando Cendes⁵, Roberto Marini Sr.⁶, Gabriela Castellano⁷, Leticia Rittner⁸ and Simone Appenzeller², ¹State University of Campinas, Campinas, Brazil, ²Medicine, State University of Campinas, Campinas, Brazil, ³pEDIATRICS, State University of Campinas, Campinas, Brazil, ⁴Rua Alexandre Fleming, Fcm09-Baraogeraldo, Campinas, Brazil, ⁵Neurology, State University of Campinas, Campinas, Brazil, ⁶Pediatric Rheumatology Unit, State University of Campinas, São Paulo, Brazil, ⁷Medical Physics, State University of Campinas, Campinas, Brazil, ⁸Electrical Engineering, State University of Campinas, Campinas, Brazil
Background/Purpose: Involvement of the central nervous system is frequently observed in childhood-onset SLE patients (cSLE). Proton magnetic spectroscopy (1H-MRS) is an important non-invasive method of…
Abstract Number: 2045 • 2015 ACR/ARHP Annual Meeting
Cross-Validation of the Pediatric Automated Neuropsychological Assessment Metrics-Cognitive Performance Scores in the Screening of Neurocognitive Impairment in Childhood-Onset Systemic Lupus Erythematosus
Jasmine Nguyen¹, Tricia Williams², Earl Silverman³ and Deborah M. Levy⁴, ¹Royal College of Surgeons in Ireland, Dublin, Ireland, ²Psychology, Hospital for Sick Children, Toronto, ON, Canada, ³Division of Rheumatology, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Neurocognitive impairment (NCI) is an important morbidity in childhood-onset systemic lupus erythematosus (cSLE); however, the gold standard formal neuropsychological assessment is difficult to access. Screening for…
Abstract Number: 2046 • 2015 ACR/ARHP Annual Meeting
Long-Term Outcomes in Cardiac Neonatal Lupus and Associated Risk Factors for Morbidity
Amit Saxena¹, Peter M. Izmirly¹, Sara Sahl¹, Deborah Friedman² and Jill P. Buyon³, ¹Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Pediatric Cardiology, New York Medical College, Valhalla, NY, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: All women with anti-Ro antibodies face the risk of cardiac neonatal lupus (cardiac NL), which presents as congenital heart block (CHB) and/or cardiomyopathy in…
Abstract Number: 2047 • 2015 ACR/ARHP Annual Meeting
A Randomised Double-Blind Placebo-Controlled Trial of Vitamin D Supplementation in Juvenile-Onset Systemic Lupus Erythematosus: Effects on Microarchitecture Measured By HR-pQCT
Glauce Lima¹, Juliane Paupitz¹, Nadia E Aikawa², Jackeline Couto Alvarenga³, Eloisa Bonfá¹ and Rosa M R Pereira⁴, ¹Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Vitamin D has an important effect in bone quality and vitamin D deficiency in Juvenile-onset Systemic Lupus Erythematosus patients (JoSLE) may be associated with…
Abstract Number: 2048 • 2015 ACR/ARHP Annual Meeting
Hospitalization Trends of Rheumatoid Arthritis and Gout in the United States: A Crossroad
Sian Yik Lim¹, Na Lu¹, Mark Fisher¹, Amar Oza¹, Sharan K. Rai², Mariano E Menendez¹ and Hyon Choi¹, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Experimental Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Rheumatoid arthritis (RA) and gout are the two most common inflammatory arthritides in the US and beyond. As hospitalization for these conditions are known…
Abstract Number: 2049 • 2015 ACR/ARHP Annual Meeting
Long Term Effectiveness of Herpes Zoster Vaccine Among Patients with Autoimmune and Inflammatory Diseases
Huifeng Yun¹, Fenglong Xie², John Baddley³, Kevin L. Winthrop⁴, Lang Chen⁵ and Jeffrey R. Curtis⁶, ¹Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Oregon Health and Science University, Portland, OR, ⁵University of Alabama at Bimingham, Birmingham, AL, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The live herpes zoster (HZ) vaccine is effective in healthy older people to reduce the incidence and burden of HZ. Recent results from a…
Abstract Number: 2050 • 2015 ACR/ARHP Annual Meeting
Herpes Zoster during the Tofacitinib Clinical Development Program for RA: Characterization of Herpes Zoster Incidence and Evaluation of Whether Herpes Zoster Predicts Subsequent Serious Infections or Malignancy
Kevin L. Winthrop¹, Yoshiya Tanaka², Kunihiro Yamaoka³, Jeffrey R. Curtis⁴, Chudy Nduaka⁵, Haiyun Fan⁵, Pinaki Biswas⁶, Tomohiro Hirose⁷, Sriram Krishnaswami⁸, Hernan Valdez⁶, Shigeyuki Toyoizumi⁷, Koshika Soma⁸ and Connie Chen⁶, ¹Oregon Health & Science University, Portland, OR, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Keio University, Tokyo, Japan, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Japan Inc, Tokyo, Japan, ⁸Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The risk of herpes zoster (HZ) was elevated within the tofacitinib clinical…
Abstract Number: 2051 • 2015 ACR/ARHP Annual Meeting
Risk for Lower Intestinal Perforations in RA Patients Treated with Tocilizumab in Comparison to Treatment with TNF Inhibitors, Rituximab, Abatacept or Conventional Synthetic Dmards
Anja Strangfeld¹, Adrian Richter², Peter Herzer³, Karin Rockwitz⁴, Winfried Demary⁵, Martin Aringer⁶, Angela Zink⁷ and Joachim Listing⁸, ¹Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Rheumatologist, Scientific Advisory Board, München, Germany, ⁴Rheumatologic Practice, Goslar, Germany, ⁵Rheumatologist, Hildesheim, Germany, ⁶Rheumatology, Medicine III, University Clinical Center, Technical University Dresden, Dresden, Germany, ⁷Epidemiologie, Deutsches Rheuma-Forschungszentrum, Berlin, Germany, ⁸Epidemiology, DRFZ, Berlin, Germany
Background/Purpose: Interleukin-6 has a direct protective effect on intestinal cells. Although several cases of lower intestinal perforations (LIP) were reported in clinical trials of tocilizumab…
Abstract Number: 2052 • 2015 ACR/ARHP Annual Meeting
Lymphoma in Patients with Rheumatoid Arthritis Treated with Biologic Drugs: Long-Term Follow-up of Risks and Lymphoma Subtypes
Karin Hellgren¹, Christer Sundström², Johan Askling³, Eva Baecklund⁴ and on behalf of the ARTIS study group, ¹Clinical Epidemiology Unit and Rheumatology Unit, Department of Medicine, Karolinska Institute at Karolinska University Hospital, Stockholm, Sweden, ²Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden, ³Clinical Epidemiology Unit and Rheumatology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁴Rheumatology, Department of Medical Sciences, University Hospital, Uppsala, Sweden
Background/Purpose: The long-term lymphoma risk in patients with rheumatoid arthritis (RA) treated with biologic disease modifying anti-rheumatic drugs (bDMARDs) remains a concern. The aim of…
Abstract Number: 2053 • 2015 ACR/ARHP Annual Meeting
Adjustment of Skeletal Muscle Mass Estimates for the Extent of Adiposity Strengthens Relationships with Functional Outcomes in Rheumatoid Arthritis
Joshua Baker¹, Jon Giles², Mary Leonard³, David Weber⁴, Jin Long⁵, Erik Jorgenson⁶ and Patricia P. Katz⁷, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, Columbia University Medical Center, NY, NY, ³Stanford University, Palo Alto, CA, ⁴Rochester University, Rochester, NY, ⁵Children's Hospital of Philadelphia, Philadelphia, PA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Rheumatology, UCSF, SF, CA
Background/Purpose: Skeletal muscle loss in rheumatoid arthritis (RA) has been described in association with poor physical functioning. Greater adiposity is simultaneously associated with both greater…
Abstract Number: 2054 • 2015 ACR/ARHP Annual Meeting
Randomized, Double-Blind, Phase 3 Study of Efficacy and Safety of ABP 501 Compared with Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis
Stanley B. Cohen¹, Mark C. Genovese², Ernest H. Choy³, Fernando Perez-Ruiz⁴, Jose L. Pablos⁵, Nan Zhang⁶ and Primal Kaur⁷, ¹Metroplex Clinical Research Center, Dallas, TX, ²Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ³Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ⁴Servicio de Reumatología, Vizcaya, Spain, ⁵Instituto de Investigacion Hospital, Madrid, Spain, ⁶Biosimilars, Amgen, Inc., Thousand Oaks, CA, ⁷Amgen, Inc., Thousand Oaks, CA
Background/Purpose: ABP 501 is being developed as a biosimilar candidate to adalimumab (Humira®), a fully human recombinant monoclonal antibody. Evidence from analytical comparisons indicates that…
Abstract Number: 2055 • 2015 ACR/ARHP Annual Meeting
A Phase III, Randomized, Double-Blind Clinical Study Comparing SB4, an Etanercept Biosimilar, with Etanercept Reference Product (Enbrel®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (52-week Results)
Jiri Vencovsky¹, Anna Sylwestrzak², Piotr Leszczyñski³, Wieslawa Porawska⁴, Asta Baranauskaite⁵, Vira Tseluyko⁶, Vyacheslav Zhdan⁷, Barbara Stasiuk⁸, Roma Milasiene⁹, Aaron Alejandro Barrera Rodriguez¹⁰, Soo Yeon Cheong¹¹, Jeehoon Ghil¹¹ and Paul Emery¹², ¹Rheumatology, Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²NZOZ Medica Pro Familia Sp. z o.o., Warsaw, Poland, ³Rheumatology and Rehabilitation, Poznan University of Medical Sciences, Poznan, Poland, ⁴Poznanski Osrodek Medyczny NOVAMED, Poznan, Poland, ⁵Lithuanian University of Health Sciences, Kaunas, Lithuania, ⁶Internal Medicine and Rheumatology, Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine, ⁷M.V.Sklifosovskyi Poltava Regional Clinical Hospital, Poltava, Ukraine, ⁸Medicome Sp. z o.o., Oswiecim, Poland, ⁹Klaipeda University Hospital, Klaipeda, Lithuania, ¹⁰Unidad de Atención Medica e Investigación en Salud (UNAMIS), Yucatán, Mexico, ¹¹Samsung Bioepis Co., Ltd., Incheon, South Korea, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: SB4 is a biologic agent developed as a biosimilar of the etanercept reference product (ETN). This study was a randomized, double-blind, multicenter study and…
Abstract Number: 2056 • 2015 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Phase III Study Comparing SB2, an Infliximab Biosimilar, to the Infliximab Reference Product (Remicade®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy: 54-Week Results
Jung-Yoon Choe¹, Nenad Prodanovic², Jaroslaw Niebrzydowski³, Ivan Staykov⁴, Eva Dokoupilova⁵, Asta Baranauskaite⁶, Roman Yatsyshyn⁷, Mevludin Mekic⁸, Wieslawa Porawska⁹, Hana Ciferska¹⁰, Krystyna Jedrychowicz-Rosiak¹¹, Agnieszka Zielinska¹², Jasmine Choi¹³, Young Hee Rho¹³ and Josef S. Smolen¹⁴, ¹Division of Rheumatology, Daegu Catholic University Medical Center, Daegu, South Korea, ²Clinical Center Banja Luka, Banja Luka, Bosnia, ³Medica Pro Familia, Gdynia, Poland, ⁴MHAT "Dr. Ivan Seliminski", AD, Sliven, Bulgaria, ⁵MEDICAL PLUS s.r.o, Uherske Hradiste, Czech Republic, ⁶Lithuanian University of Health Sciences, Kaunas, Lithuania, ⁷SHEI Ivano-Frankivsk NMU, Ivano-Frankivsk, Ukraine, ⁸University Clinic Centre Sarajevo, Sarajevo, Bosnia, ⁹Poznanski Osrodek Medyczny NOVAMED, Poznan, Poland, ¹⁰Revmatologicky ustav, Praha 2, Czech Republic, ¹¹MCBK S.C., Grodzisk Mazowiecki, Poland, ¹²Medica Pro Familia Sp. z o.o. Spolka Komandytowo-Akcyjna, Warszawa, Poland, ¹³Samsung Bioepis Co., Ltd., Incheon, South Korea, ¹⁴Medical University of Vienna, Vienna, Austria
Background/Purpose: SB2 is developed as a biosimilar of the infliximab reference product (INF). 30-week efficacy and safety results from a randomized phase III study were…
Abstract Number: 2057 • 2015 ACR/ARHP Annual Meeting
Antibodies to Infliximab in Remicade-Treated Rheumatic Patients Show Identical Reactivity Towards Biosimilars
Begoña Ruiz-Argüello¹, Ainara Maguregui¹, Ainhoa Ruiz del Agua¹, Dora Pascual-Salcedo², Ana Martínez², Teresa Jurado³, Chamaida Plasencia⁴, Alejandro Balsa⁵, Francisca Llinares-Tello⁶, José Rosas⁷, Nerea Torres¹, Antonio Martínez¹ and Daniel Nagore¹, ¹R&D, Progenika-Grifols, Derio, Spain, ²Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, ³Immunology, La Paz University Hospital-Idipaz, Madrid, Spain, ⁴Rheumatology Unit, La Paz University Hospital-Rheumatology, Madrid, Spain, ⁵Rheumatology, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ⁶Clinical Analysis, Hospital Marina Baixa, Clinical Analysis, Villajoyosa, Spain, ⁷Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain
Background/Purpose: Infliximab (IFX) is the most immunogenic of anti-TNFα drugs available to treat patients with rheumatic diseases. The recent approval of the first infliximab biosimilars in…
Abstract Number: 2058 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Rituximab Biosimilar Candidate (CT-P10) and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase I Randomized Controlled Trial over 72 Weeks
Dae-Hyun Yoo¹, Won Park², Chang-Hee Suh³, Seung-Cheol Shim⁴, Slawomir Jeka⁵, Fidencio Cons Molina⁶, Pawel Hrycaj⁷, Wolfgang Spieler⁸, Piotr Wiland⁹, Jan Brzezicki¹⁰, Eun Young Lee¹¹, Francisco G. Medina-Rodriguez¹², Pavel Shesternya¹³, Sebastiao Radominski¹⁴, Marina Stanislav¹⁵, Volodymyr Kovalenko¹⁶, Donghyuk Sheen¹⁷, Leysan Myasoutova¹⁸, Mie Jin Lim¹⁹, Jung-Yoon Choe²⁰, Taek S. Kwon²¹ and Sang Joon Lee²¹, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ³Department of Rheumatology, Ajou University Hospital, Suwon, South Korea, ⁴Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, ⁵University Hospital Nr 2 Dr. Jan Biziel, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Clinic of Rheumatology and Connective Tissue Diseases, Bydgoszcz, Poland, ⁶Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, ⁷Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland, ⁸Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ⁹Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ¹⁰Wojewodzki Szpital Zespolony w Elablagu, Elblag, Poland, ¹¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ¹²Rheumatology, LaSalle University, Mexico City, Mexico, ¹³Rheumatology Department, Krasnoyarsk State Medical University, Krasnoyarsk, Russia, ¹⁴CETI-Centro de estudos em Terapias Inovadoras, Universidade Federal do Parana, Curitiba, Brazil, ¹⁵Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russia, ¹⁶Section of Non-coronarogenic Myocardial Diseases and Clinical Rheumatology, National Scientific Center, Kiev, Ukraine, ¹⁷Rheumatology, Eulji University Hospital, Daejeon, South Korea, ¹⁸City Reumatology Center, Research Medical Complex Vashe Zdorovie, Kazan, Russia, ¹⁹Division of Rheumatology, Departments of Internal Medicine, Inha University Hospital, Incheion, South Korea, ²⁰Internal Medicine, Catholic University of Daegu, School of Medicine, Daegu, South Korea, ²¹CELLTRION, Inc., Incheon, South Korea
Background/Purpose: CT-P10 is a biosimilar candidate of innovator rituximab (RTX). PK profile and clinical data up to week 24 has been reported at ACR 20131.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].